Severe Epistaxis Due to Risankizumab: A Case Report

Risankizumab is a novel treatment for plaque psoriasis, approved for treatment in the US in 2019. It is a humanized monoclonal antibody that demonstrates high efficacy and safety, both in short-term and long-term usage. Like many modern medications, risankizumab has some reported adverse effects. The most common of these reported adverse effects, affecting more than 20% of users, is nasopharyngitis. This case report discusses a 76-year-old female patient who presented to the emergency department for severe epistaxis while receiving risankizumab as treatment for plaque psoriasis.